Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 18/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860832 | 0.90 | ADORA2B (0.38) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4890173 | 0.89 | ADORA2A (0.42) | ADORA2AADORA2BADORA1C5AR1HSD11B1 | |
| SCHEMBL4900650 | 0.88 | ADORA2B (0.47) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4769025 | 0.86 | C5AR1 (0.37) | ADORA2AADORA2BADORA1C5AR1HSD11B1 | |
| SCHEMBL4769016 | 0.86 | C5AR1 (0.37) | ADORA2AADORA2BADORA1C5AR1HSD11B1 | |
| SCHEMBL4891723 | 0.84 | C5AR1 (0.42) | ADORA2AADORA2BADORA1C5AR1HSD11B1 | |
| SCHEMBL4897242 | 0.82 | ADORA2B (0.42) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4867852 | 0.81 | PARG (0.37) | — | |
| SCHEMBL4866193 | 0.81 | PDE4A (0.39) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4890722 | 0.81 | ADORA2B (0.48) | ADORA2AADORA2BADORA1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.